EssilorLuxottica Profit Beats Forecasts on AI Glasses, Myopia Sales

EssilorLuxottica reported a 15% surge in first-half adjusted operating profit to €2.75 billion, beating the €2.46 billion consensus, as AI-powered smart glasses and myopia management products fueled revenue growth. The Franco-Italian eyewear giant saw second-quarter revenue rise 8.7% at constant exchange rates, propelled by a near doubling of sales from its Meta-partnered AI glasses and a 24% jump in myopia portfolio revenue.

July 28, 2026 , Inside AI — EssilorLuxottica reported a 15% surge in first-half adjusted operating profit to €2.75 billion , handily beating the €2.46 billion consensus, as AI-powered smart glasses and myopia management products fueled revenue growth. The Franco-Italian eyewear giant, known for its Ray-Ban brand, saw second-quarter revenue rise 8.7% at constant exchange rates, propelled by a near doubling of sales from its Meta -partnered AI glasses and a 24% jump in myopia portfolio revenue. The profit beat comes despite revenue of €7.7 billion slightly missing the €7.8 billion analyst forecast. The company did not detail the margin outperformance, but it aligns with a trend of European firms like Philips benefiting from U.S. tariff-related reimbursements. This suggests external trade dynamics may be padding bottom lines, though EssilorLuxottica's core eyewear and eyecare business still posted mid-single-digit growth. The standout performer was the AI glasses segment, developed with Meta . Sales nearly doubled, underscoring consumer appetite for wearable AI despite broader market skepticism. In late June, the partners launched a new line of lower-priced smart glasses starting at $299 , manufactured outside EssilorLuxottica's own facilities. This move could democratize access and counter concerns that have halved the company's share price since mid-November. Myopia management products also shone, with revenue up 24% . This reflects a growing global focus on vision health, particularly among younger demographics where screen time is driving a myopia epidemic. EssilorLuxottica's investment in this niche is paying off, as parents and health systems seek solutions beyond traditional corrective lenses. The Profit Puzzle: Tariffs and Hidden Tailwinds The lack of a detailed profit explanation raises questions. Some analysts point to U.S. tariff reimbursements as a possible factor, echoing Philips ' recent experience. If true, this would mean the beat is partly policy-driven, not purely operational. Investors should watch whether such benefits are sustainable, especially as trade tensions evolve. The company's confirmation of its medium-term outlook suggests confidence, but the share price slump indicates lingering doubts about smart glasses profitability. EssilorLuxottica's partnership with Meta is pivotal. The new $299 glasses target a mass market, but manufacturing outside the company's own facilities could impact quality control or margins. A recent study on wearable AI adoption https://arxiv.org/abs/2306.09302 highlights that price and privacy concerns remain key barriers. By lowering the entry point, EssilorLuxottica may accelerate adoption, but it must balance brand prestige with accessibility. Smart Glasses: Boom or Bubble? The near-doubling of AI glasses sales is impressive, but the segment is still nascent. Market volatility and competition from tech giants like Apple loom. EssilorLuxottica's core business provides a buffer, yet the myopia portfolio's 24% growth signals a strategic shift toward health-tech. This diversification could insulate the company if smart glasses hype fades. Revenue from the core eyewear and eyecare division grew in the mid-single digits, a steady but unspectacular performance. This underscores the importance of new growth engines. The company's ability to integrate AI and health features into everyday wearables will likely define its next decade. For now, the profit beat offers a reprieve, but sustained execution is critical. Looking ahead, all eyes are on the holiday season, when the new $299 glasses hit shelves. If they replicate the success of earlier models, EssilorLuxottica could reverse its stock slide. However, with major shareholder Delfin facing uncertainty, external factors may still sway sentiment. The company's medium-term outlook remains intact, but the path is fraught with both opportunity and risk.